WO1988002700A1 - Apparatus and method for controlling transmission of defects - Google Patents

Apparatus and method for controlling transmission of defects Download PDF

Info

Publication number
WO1988002700A1
WO1988002700A1 PCT/GB1987/000702 GB8700702W WO8802700A1 WO 1988002700 A1 WO1988002700 A1 WO 1988002700A1 GB 8700702 W GB8700702 W GB 8700702W WO 8802700 A1 WO8802700 A1 WO 8802700A1
Authority
WO
WIPO (PCT)
Prior art keywords
participant
test result
disorder
legible
test
Prior art date
Application number
PCT/GB1987/000702
Other languages
French (fr)
Inventor
Labib Alfred Nassim
Original Assignee
Mainframe Data Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868624013A external-priority patent/GB8624013D0/en
Application filed by Mainframe Data Limited filed Critical Mainframe Data Limited
Publication of WO1988002700A1 publication Critical patent/WO1988002700A1/en
Priority to NO882489A priority Critical patent/NO882489L/en
Priority to DK306588A priority patent/DK306588D0/en

Links

Classifications

    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K19/00—Record carriers for use with machines and with at least a part designed to carry digital markings
    • G06K19/06—Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code
    • G06K19/08—Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code using markings of different kinds or more than one marking of the same kind in the same record carrier, e.g. one marking being sensed by optical and the other by magnetic means
    • G06K19/10—Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code using markings of different kinds or more than one marking of the same kind in the same record carrier, e.g. one marking being sensed by optical and the other by magnetic means at least one kind of marking being used for authentication, e.g. of credit or identity cards
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B42—BOOKBINDING; ALBUMS; FILES; SPECIAL PRINTED MATTER
    • B42D—BOOKS; BOOK COVERS; LOOSE LEAVES; PRINTED MATTER CHARACTERISED BY IDENTIFICATION OR SECURITY FEATURES; PRINTED MATTER OF SPECIAL FORMAT OR STYLE NOT OTHERWISE PROVIDED FOR; DEVICES FOR USE THEREWITH AND NOT OTHERWISE PROVIDED FOR; MOVABLE-STRIP WRITING OR READING APPARATUS
    • B42D25/00—Information-bearing cards or sheet-like structures characterised by identification or security features; Manufacture thereof
    • B42D25/30—Identification or security features, e.g. for preventing forgery
    • B42D25/305—Associated digital information
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B42—BOOKBINDING; ALBUMS; FILES; SPECIAL PRINTED MATTER
    • B42D—BOOKS; BOOK COVERS; LOOSE LEAVES; PRINTED MATTER CHARACTERISED BY IDENTIFICATION OR SECURITY FEATURES; PRINTED MATTER OF SPECIAL FORMAT OR STYLE NOT OTHERWISE PROVIDED FOR; DEVICES FOR USE THEREWITH AND NOT OTHERWISE PROVIDED FOR; MOVABLE-STRIP WRITING OR READING APPARATUS
    • B42D25/00—Information-bearing cards or sheet-like structures characterised by identification or security features; Manufacture thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B42—BOOKBINDING; ALBUMS; FILES; SPECIAL PRINTED MATTER
    • B42D—BOOKS; BOOK COVERS; LOOSE LEAVES; PRINTED MATTER CHARACTERISED BY IDENTIFICATION OR SECURITY FEATURES; PRINTED MATTER OF SPECIAL FORMAT OR STYLE NOT OTHERWISE PROVIDED FOR; DEVICES FOR USE THEREWITH AND NOT OTHERWISE PROVIDED FOR; MOVABLE-STRIP WRITING OR READING APPARATUS
    • B42D25/00—Information-bearing cards or sheet-like structures characterised by identification or security features; Manufacture thereof
    • B42D25/20—Information-bearing cards or sheet-like structures characterised by identification or security features; Manufacture thereof characterised by a particular use or purpose
    • B42D25/22—Information-bearing cards or sheet-like structures characterised by identification or security features; Manufacture thereof characterised by a particular use or purpose for use in combination with accessories specially adapted for information-bearing cards
    • B42D2035/08—
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B42—BOOKBINDING; ALBUMS; FILES; SPECIAL PRINTED MATTER
    • B42D—BOOKS; BOOK COVERS; LOOSE LEAVES; PRINTED MATTER CHARACTERISED BY IDENTIFICATION OR SECURITY FEATURES; PRINTED MATTER OF SPECIAL FORMAT OR STYLE NOT OTHERWISE PROVIDED FOR; DEVICES FOR USE THEREWITH AND NOT OTHERWISE PROVIDED FOR; MOVABLE-STRIP WRITING OR READING APPARATUS
    • B42D25/00—Information-bearing cards or sheet-like structures characterised by identification or security features; Manufacture thereof
    • B42D25/20—Information-bearing cards or sheet-like structures characterised by identification or security features; Manufacture thereof characterised by a particular use or purpose

Definitions

  • This invention is concerned with apparatus and methods for preventing or reducing the risks of transmission of defects from one participant to another, e.g. from one human being to another human being or to an organisation. More particularly it is concerned with such apparatus and methods for i.e. preventing, or substantially reducing the risk of transmission of a communicable disease or disorder.
  • communicable disease or disorder we include, for example infectious ailments be they viral, bacterial or the like and genetically transmissible disorders.
  • the invention may find application amongst humans who are contemplating intimate contact or contemplating donation of body fluids or material for reception or use by a second participant.
  • the invention may also be useful to persons or organisations responsible for such donations as blood banks, hospitals, transfusion centres, medical teams and the like.
  • the invention could even be useful in the field of animal husbandry as a means of controlling undesirable disease or disorder under human supervised breeding conditions.
  • the invention may be a systematic control method to help stop the spread of communicable disease or disorder in which medical treatment is not required.
  • the invention has a principal application in stemming further spread of sexually communicable diseases amongst humans, notably Acquired Immune Deficiency Syndrome (AIDS) for which there is currently no cure and to a lesser extent, the venereal diseases such as syphilis, gonorrhoea or herpes.
  • the invention may also find application in preventing, or substantially reducing the risks of transmission of a genetic disorder from one generation to another e.g. to an offspring of a participant.
  • the invention may be useful in controlling such communicable defects as, for example, mongolism. cystic fibrosis, haemophilia, diabetes and sickle cell anaemia.
  • First Participant an individual contemplating intimate contact with or donation to a second participant; or a first animal for breeding or donation purposes.
  • Defect - communicable disease or disorder being infectious or genetic which may adversely affect the health or function of an individual or animal.
  • the term is used to include any sexually communicable disease amongst living beings, especially AIDS.
  • “Second Participant” an individual contemplating intimate contact with a user, a second animal for breeding or donation-receiving purposes or an individual, group, team, organisation and the like which receives or monitors donated body fluid or material, or contemplates such receipt.
  • body fluid or material that may be donated we include human or animal blood that can be used either immediately or subsequently for transfusion, for conversion into blood products such as separation into blood plasma, or concentration and separation in factor VIII, and e.g. bone marrow for immediate or subsequent transplantation.
  • organs for transplantation for example, one kidney from an individual (first participant) to a related individual (second participant) when both such individuals are live or posthumous donation of vital organs such as kidneys, heart, lungs in the event of an untimely death of first participant.
  • the invention is useful in preventing transmission of disease or disorder from a potential carrier, which may be anyone or any animal within a given population, to a potential recipient of that disease or disorder.
  • the invention may therefore be useful to people concerned with animal husbandry but principally to individuals as first and second participants contemplating intimate contact where there exists a risk of acquiring an infectious disease. As will become apparent this can be provided by independent test result for assessment by a second participant.
  • AIDS AIDS.
  • Three possible methods of controlling the spread include find a cure, find a vaccine or separate the AIDS infected carriers from intimate or other risky contact with the rest of the population.
  • the first two solutions are currently considered to be unobtainable in the immediate future.
  • the separation proposal has been the only practicable step at the present time.
  • the majority of organised attempts to isolate carriers of the AIDS human immunodeficiency virus HIV from contact with the remaining population have been directed at isolating the sick from the healthy, i.e. those infected from those who are not.
  • the AIDS virus has a long incubation period and for this reason any control measures are likely to affect the sensitive issue of personal liberty.
  • the present invention is based on a surprisingly different approach to the problem in that it is concerned with isolating the healthy from the sick rather than the converse. Any attempts by individuals to isolate themselves from potential or actual carriers of AIDS have been haphazard. It has been observed that individuals at risk of contacting AIDS have limited the number of intimate contacts made with others.
  • apparatus useful in a method of controlling transmission of a communicable disease or disorder comprising an identification means bearing identity information relating to a first participant and one or more security features, and a storage medium carrying legible or retrievable information concerning a test result performed upon or in connection with the first participant, the test result relating to a communicable disease or disorder.
  • a method of controlling transmission of a defect from a first to second comprising:
  • step (f) permitting contact between first and second participant or donation from first to second participant if step (e) results in a decision to accept.
  • the first participant may repeat that test or have a different test for another communicable disease or disorder performed at any stage after (a).
  • the first participant may decide to terminate the sequence before step (d) if the particular test is unfavourable, e.g. after a diagnosis of AIDS antibody positive.
  • the result may be stored legibly on an independently issued certificate and this proof of result may be presented to or sent to the individual (first participant) immediately upon completion of the test. The individual will then be at liberty to disclose this to any second participant of his choosing.
  • the test result may be stored on or in electronic, optical or magnetic storage medium such as a database and subsequently retrieved by the second participant with express or implicit permission from the first participant. This may be achieved by the second participant interrogating the appropriate storage medium to retrieve the result and possibly have a permanent record of it by certificate, print out or the like. This may be done in the presence of the first participant or by furnishing consent to a data centre operator who stores a plurality of test results on a specific database. A second participant may be given a secret access code from the first participant to retrieve the test result from the storage medium (e.g. database) without the intermediary of an operator.
  • the storage medium e.g. database
  • Such interrogation of a database may produce a result by audio and/or visual means such as, for example, a printed record being obtained at the request of the recipient.
  • the identification means may comprise a personal identity card similar to plastic credit cards in common use.
  • the identity information may include a photograph, a name, a legible code and/or a secret code.
  • security features include predetermined patterns and/or holograms.
  • the storage medium may simply comprise paper such as a certificate bearing a legible test result giving date, type and result of test, plus information identifying the first participant.
  • the storage medium may be electronic, optical or magnetic, in which case the test result would be retrievable and then could be made permanently legible if desired.
  • the identification means is a personal card bearing a magnetic strip having the test result stored on it. The result can be retrieved subsequently.
  • One convenient test for a first participant is carried out on a blood sample, e.g. the test for AIDS antibodies.
  • the present apparatus and method is especially useful in controlling the further spread of sexually transmissible disease or disorder.
  • the present apparatus can be used in conjunction with means for retrieving a non-legible test result carried on the storage medium.
  • means for retrieving a non-legible test result carried on the storage medium For example an electronic decoder and display unit optionally with printing means.
  • Figure 1 shows a front and reverse sides of identification means
  • Figure 2 shows a storage medium carrying legible test result
  • Figures 3 and 4 show flow charts of methods that may be carried out using the apparatus features.
  • this embodiment relates to proposed intimate contact between a first participant and a second individual participant. It may equally apply with some modifications where intimate contact is proposed between animals, under human-supervised breeding conditions or for establishing the suitability of donated body fluid or material for subsequent transfusion or other use. All participants may subscribe to a defect screening system in which a data centre, controlled by an operator, stores test results on a database and permits retrieval of results under authorised terms.
  • the first participant is provided with a card similar to a credit card 1.
  • the card has a legible code 4, a secret code((invisible) , a photograph 2 of the holder, and a hologram (not shown). It should be noted that the name and signature of the user are unnecessary.
  • the card also has a logo 3, an address 5 and telephone number 6 of a data centre which stores the test results.
  • the first participant has his blood tested at least once, preferably periodically, at a suitable location e.g. one approved by the above noted screening system operator.
  • the data centre would verify the authenticity of the card and note the legible code.
  • the result of the test, the type of test, the date of the test and the code on the card would be sent to the operator if it is to be stored on a database for subsequent retrieval. This information could even be applied to a magnetic, electronic or optical recording strip on one side of the card (not shown).
  • test result can be compiled as a certificate, see Figure 2, which shows a tangible certificate 8 having optional logo 3, photograph 2 of first participant, security feature 4, date of test 9, type of test 10 and result of test 11. This certificate can be retained by the first participant. At any time that the first participant may wish to
  • Plastic cards are only one of many possible identification means to establish a link between first participant, the test result, the second participant and the storage means, e.g. database.
  • Operators may wish to communicate anonymous data across regions and countries in order to improve the method and freedom of first participants.
  • test result data in such a way as to enhance the ease of use while preventing fraud.
  • Participants using the apparatus and method may therefore make substantial contributions to controlling the spread of communicable disease or disorder and consequently enhancing the health and well being of the human or animal population.
  • Figure 3 For a general application of the method which illustrates the use of the apparatus the reader is referred to Figure 3 whilst for a more specific example, based on the Figures 1 and 2 apparatus the.reader is referred to Figure 4.
  • the flowcharts themselves are self-explanatory with an index given relating to each particular step in the method as defined above.
  • the invention can be seen to involve testing of living beings or live organs or useful body fluid/material for certain physical parameters and a secure system of passing information to individuals or groups etc. at the choice of the first participant.
  • Testing for presence or absence of defects is meant to include all means and methods for performing such tests, for example by testing samples of blood, urine, skin, flesh, organs, semen, breath, hair or nails. In some cases certain tests may not require removal of a sample but these may be performed in situ.
  • An important application of the present invention is in the screening of blood donations by blood banks acting as second participants.
  • Present arrangements for screening are not altogether satisfactory and in certain countries blood is donated for financial reward.
  • the donors first participants
  • the blood bank unknowingly accepts their donation and payment is made. It is only after payment that such blood is tested and sometimes destroyed because of the presence of a potentially harmful defect.
  • these unnecessary expenses and risks may be circumvented, particularly if the test results are securely stored on a database and access thereto is carefully controlled.
  • the data centre may pair or twin participants by e.g. supplying both participants' identity card numbers to the operator. When such links are present in the data centre all such participants may be notified who could have become infected by e. . AIDS virus through contact with other participants. When the participant interrogates their own data, they may receive a warning to have medical attention and/or exercise caution in future intimate contacts or donations.

Landscapes

  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Transmitters (AREA)
  • Communication Control (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Apparatus useful in preventing or reducing risks of transmitting an infectious disease, primarily AIDS, or genetic disorder, comprises identification means such as a personal card bearing identity particulars of a first participant and security feature(s) and a storage medium such as certificate or database, bearing legible or retrievable test result data concerning the particular defect. A second participant consults the result before permitting intimate contact or accepting a donation of blood, body tissue or similar material.

Description

UΪLE
Apparatus and method for controlling Transmission .of Defects
This invention is concerned with apparatus and methods for preventing or reducing the risks of transmission of defects from one participant to another, e.g. from one human being to another human being or to an organisation. More particularly it is concerned with such apparatus and methods for i.e. preventing, or substantially reducing the risk of transmission of a communicable disease or disorder. By communicable disease or disorder we include, for example infectious ailments be they viral, bacterial or the like and genetically transmissible disorders.
The invention may find application amongst humans who are contemplating intimate contact or contemplating donation of body fluids or material for reception or use by a second participant. The invention may also be useful to persons or organisations responsible for such donations as blood banks, hospitals, transfusion centres, medical teams and the like. The invention could even be useful in the field of animal husbandry as a means of controlling undesirable disease or disorder under human supervised breeding conditions.
Use of the invention may be a systematic control method to help stop the spread of communicable disease or disorder in which medical treatment is not required. As will become apparent, the invention has a principal application in stemming further spread of sexually communicable diseases amongst humans, notably Acquired Immune Deficiency Syndrome (AIDS) for which there is currently no cure and to a lesser extent, the venereal diseases such as syphilis, gonorrhoea or herpes. The invention may also find application in preventing, or substantially reducing the risks of transmission of a genetic disorder from one generation to another e.g. to an offspring of a participant. In this field of hereditary defects the invention may be useful in controlling such communicable defects as, for example, mongolism. cystic fibrosis, haemophilia, diabetes and sickle cell anaemia.
The following terms and expressions are used throughout the description and claims to include the following:
"First Participant": - an individual contemplating intimate contact with or donation to a second participant; or a first animal for breeding or donation purposes.
"Defect": - communicable disease or disorder being infectious or genetic which may adversely affect the health or function of an individual or animal. The term is used to include any sexually communicable disease amongst living beings, especially AIDS.
"Second Participant":- an individual contemplating intimate contact with a user, a second animal for breeding or donation-receiving purposes or an individual, group, team, organisation and the like which receives or monitors donated body fluid or material, or contemplates such receipt.
As examples of body fluid or material that may be donated we include human or animal blood that can be used either immediately or subsequently for transfusion, for conversion into blood products such as separation into blood plasma, or concentration and separation in factor VIII, and e.g. bone marrow for immediate or subsequent transplantation. We also include organs for transplantation, for example, one kidney from an individual (first participant) to a related individual (second participant) when both such individuals are live or posthumous donation of vital organs such as kidneys, heart, lungs in the event of an untimely death of first participant. Individuals wishing to donate any such organs may carry a donor card expressing a wish or preference for a donation or, alternatively, the decision to donate may be made by representatives of the donor, for example, the parents (as second participants in a monitoring function) of an individual recently killed. Before a medical team may wish to use any donated organs they may require up-to-date information in respect of potentially damaging defects such as contamination by the AIDS virus or subject to haemophilia genetic disorder and the like. As a suitable body fluid which may be donated by individuals or animals we also include semen which may be stored in a sperm bank and used for artificial insemination. It may be advantageous for the recipient (second participant) of such semen to have up to date information in respect of any required defect by having access to a test result in respect of that defect for such donated material.
The invention is useful in preventing transmission of disease or disorder from a potential carrier, which may be anyone or any animal within a given population, to a potential recipient of that disease or disorder. The invention may therefore be useful to people concerned with animal husbandry but principally to individuals as first and second participants contemplating intimate contact where there exists a risk of acquiring an infectious disease. As will become apparent this can be provided by independent test result for assessment by a second participant.
In many countries there is a considerable anxiety over the spread of the communicable disease known as
AIDS. Three possible methods of controlling the spread include find a cure, find a vaccine or separate the AIDS infected carriers from intimate or other risky contact with the rest of the population. The first two solutions are currently considered to be unobtainable in the immediate future. The separation proposal has been the only practicable step at the present time.
The importance of controlling further spread of AIDS into the non-AIDS infected population is becoming more and more important in the united Kingdom and is already a problem in countries such as the United States where a large proportion of the homosexual community are AIDS infected.
The majority of organised attempts to isolate carriers of the AIDS human immunodeficiency virus HIV from contact with the remaining population have been directed at isolating the sick from the healthy, i.e. those infected from those who are not. The AIDS virus has a long incubation period and for this reason any control measures are likely to affect the sensitive issue of personal liberty. The present invention is based on a surprisingly different approach to the problem in that it is concerned with isolating the healthy from the sick rather than the converse. Any attempts by individuals to isolate themselves from potential or actual carriers of AIDS have been haphazard. It has been observed that individuals at risk of contacting AIDS have limited the number of intimate contacts made with others. Use of the present invention permits a still further and significant reduction of risks and therefore may save lives and reduce anxiety and stress amongst individuals who use the apparatus and/or method according to the invention. According to a primary aspect of this invention there is provided apparatus useful in a method of controlling transmission of a communicable disease or disorder comprising an identification means bearing identity information relating to a first participant and one or more security features, and a storage medium carrying legible or retrievable information concerning a test result performed upon or in connection with the first participant, the test result relating to a communicable disease or disorder.
According to a second aspect of this invention there is provided a method of controlling transmission of a defect from a first to second comprising:
(a) supplying the first participant with identification means,
(b) performing a test for presence or absence of the defect upon or in relation to the first participant,
(cl) producing in legible or retrievable form a test result on a storage medium identifying the first participant or (c2) storing the test result in a database followed by (c3) retrieval of that result,
(d) informing the second participant of the test result,
(e) establishing an accept or reject decision by or on behalf of the second participant, and
(f) permitting contact between first and second participant or donation from first to second participant if step (e) results in a decision to accept. Optionally the first participant may repeat that test or have a different test for another communicable disease or disorder performed at any stage after (a). Furthermore, the first participant may decide to terminate the sequence before step (d) if the particular test is unfavourable, e.g. after a diagnosis of AIDS antibody positive.
In the apparatus and step (cl) of the method the result may be stored legibly on an independently issued certificate and this proof of result may be presented to or sent to the individual (first participant) immediately upon completion of the test. The individual will then be at liberty to disclose this to any second participant of his choosing. Alternatively, the test result may be stored on or in electronic, optical or magnetic storage medium such as a database and subsequently retrieved by the second participant with express or implicit permission from the first participant. This may be achieved by the second participant interrogating the appropriate storage medium to retrieve the result and possibly have a permanent record of it by certificate, print out or the like. This may be done in the presence of the first participant or by furnishing consent to a data centre operator who stores a plurality of test results on a specific database. A second participant may be given a secret access code from the first participant to retrieve the test result from the storage medium (e.g. database) without the intermediary of an operator.
Such interrogation of a database may produce a result by audio and/or visual means such as, for example, a printed record being obtained at the request of the recipient. It may be convenient for the identification means to comprise a personal identity card similar to plastic credit cards in common use. The identity information may include a photograph, a name, a legible code and/or a secret code. Examples of security features include predetermined patterns and/or holograms. The storage medium may simply comprise paper such as a certificate bearing a legible test result giving date, type and result of test, plus information identifying the first participant. Alternatively "the storage medium may be electronic, optical or magnetic, in which case the test result would be retrievable and then could be made permanently legible if desired.
In one embodiment the identification means is a personal card bearing a magnetic strip having the test result stored on it. The result can be retrieved subsequently.
One convenient test for a first participant is carried out on a blood sample, e.g. the test for AIDS antibodies. The present apparatus and method is especially useful in controlling the further spread of sexually transmissible disease or disorder.
The present apparatus can be used in conjunction with means for retrieving a non-legible test result carried on the storage medium. For example an electronic decoder and display unit optionally with printing means.
In order that the invention may be illustrated and readily carried into effect, embodiments thereof will now be described by way of example only with reference to the accompanying drawings, in which:
Figure 1 shows a front and reverse sides of identification means, Figure 2 shows a storage medium carrying legible test result, and
Figures 3 and 4 show flow charts of methods that may be carried out using the apparatus features. Referring to the drawings and particularly Figures 1 and 2, this embodiment relates to proposed intimate contact between a first participant and a second individual participant. It may equally apply with some modifications where intimate contact is proposed between animals, under human-supervised breeding conditions or for establishing the suitability of donated body fluid or material for subsequent transfusion or other use. All participants may subscribe to a defect screening system in which a data centre, controlled by an operator, stores test results on a database and permits retrieval of results under authorised terms.
The first participant is provided with a card similar to a credit card 1. The card has a legible code 4, a secret code((invisible) , a photograph 2 of the holder, and a hologram (not shown). It should be noted that the name and signature of the user are unnecessary. The card also has a logo 3, an address 5 and telephone number 6 of a data centre which stores the test results. The first participant has his blood tested at least once, preferably periodically, at a suitable location e.g. one approved by the above noted screening system operator. The data centre would verify the authenticity of the card and note the legible code. The result of the test, the type of test, the date of the test and the code on the card would be sent to the operator if it is to be stored on a database for subsequent retrieval. This information could even be applied to a magnetic, electronic or optical recording strip on one side of the card (not shown).
Instead of storage the test result can be compiled as a certificate, see Figure 2, which shows a tangible certificate 8 having optional logo 3, photograph 2 of first participant, security feature 4, date of test 9, type of test 10 and result of test 11. This certificate can be retained by the first participant. At any time that the first participant may wish to
^establish absence of defect to a second participant he may interrogate this database in the presence of that second participant or otherwise expressly consent to interrogation in his absence. The secret code may be used to give right of access to this database. An alternative way of presenting this data after retrieval would be for a data centre operator to produce, on demand, a certificate explaining the test results of the first participant. At any time desired the first participant may show this certificate of independent test to a second participant to establish absence of defect. At that time a more informed decision to permit intimate contact or accept donation can be made thus helping control of the particular disease of disorder tested. It should be the responsibility of the second participant to interpret test results to determine whether intimate contact or receipt/use of donation can be permitted.
Plastic cards are only one of many possible identification means to establish a link between first participant, the test result, the second participant and the storage means, e.g. database.
Operators may wish to communicate anonymous data across regions and countries in order to improve the method and freedom of first participants.
Many feasible ways exist for presenting test result data in such a way as to enhance the ease of use while preventing fraud. For example, by telephone, by videotex, by certificate and the like. Participants using the apparatus and method may therefore make substantial contributions to controlling the spread of communicable disease or disorder and consequently enhancing the health and well being of the human or animal population. For a general application of the method which illustrates the use of the apparatus the reader is referred to Figure 3 whilst for a more specific example, based on the Figures 1 and 2 apparatus the.reader is referred to Figure 4. The flowcharts themselves are self-explanatory with an index given relating to each particular step in the method as defined above.
The invention can be seen to involve testing of living beings or live organs or useful body fluid/material for certain physical parameters and a secure system of passing information to individuals or groups etc. at the choice of the first participant.
Testing for presence or absence of defects is meant to include all means and methods for performing such tests, for example by testing samples of blood, urine, skin, flesh, organs, semen, breath, hair or nails. In some cases certain tests may not require removal of a sample but these may be performed in situ.
An important application of the present invention is in the screening of blood donations by blood banks acting as second participants. Present arrangements for screening are not altogether satisfactory and in certain countries blood is donated for financial reward. In such a situation the donors (first participants) can be infected by a communicable disease such as AIDS or hepatitis virus but the blood bank unknowingly accepts their donation and payment is made. It is only after payment that such blood is tested and sometimes destroyed because of the presence of a potentially harmful defect. By using the present apparatus or method these unnecessary expenses and risks may be circumvented, particularly if the test results are securely stored on a database and access thereto is carefully controlled.
The data centre, if used, may pair or twin participants by e.g. supplying both participants' identity card numbers to the operator. When such links are present in the data centre all such participants may be notified who could have become infected by e. . AIDS virus through contact with other participants. When the participant interrogates their own data, they may receive a warning to have medical attention and/or exercise caution in future intimate contacts or donations.

Claims

1. Apparatus useful in a method of controlling transmission of a communicable disease or disorder comprising an identification means bearing identity information relating to a first participant and one or more security features, and a storage medium carrying legible or retrievable information concerning a test result performed upon or in connection with the first participant, the test result relating to a communicable disease or disorder.
2. Apparatus as claimed in Claim 1 in which the identification means comprises a personal card.
3. Apparatus as claimed in Claim 1 or 2 in which the identity information comprises one or more of the following: a photograph of the first participant, a legible code, a name or signature.
4. Apparatus as claimed in any preceding claim in which the security feature comprises a predetermined pattern, a hologram and/or a magnetically or optically readable access code.
5. Apparatus as claimed in any preceding claim in which the storage medium bears a legible test result, optionally in the form of a certificate.
6. Apparatus as claimed in any one of Claims 1 to 4, in which the storage medium is magnetic or optical or electronic and carries a retrievable test result, such as a database or data centre.
7. Apparatus as claimed in Claim 6 comprising a personal card bearing a magnetic strip which carries a retrievable test result and/or a non-legible access code as a security feature.
8. Apparatus as claimed in any preceding claim in which the test result relates to a test performed on a first participant's blood.
9. Apparatus as claimed in any preceding claim in which the test result relates to a sexually communicable disease or disorder.
10. Apparatus as claimed in Claim 9 in which the test result relates to presence or absence of Human immunodeficiency virus HIV.
11. Apparatus as claimed in any preceding claim in combination with retrieval means for retrieving a stored test result carried on the storage medium.
12. Apparatus as claimed in Claim 11 in which the retrieval apparatus can display and/or print the test result.
13. Apparatus useful in a method of controlling transmission of a communicable disease or disorder substantially as herein described.
14. Apparatus as claimed in Claim 13 as illustrated in Figure 1 or 2 of the accompanying drawings.
15. A method of controlling transmission of a communicable disease or disorder from a first participant to a second participant comprising:
(a) supplying the first participant with identification means,
(b) performing a test for presence or absence of the defect upon or in relation to the first participant,
(cl) producing in legible or retrievable form a test result identifying the first participant, optionally (c2) storing the test result in a storage means, then (c3) retrieving the result for presentation,
(d) informing the second participant of the test result,
(e) establishing an accept or reject decision by or on behalf of the second participant, and
(f) permitting contact or donation between first and second participants if step (e) results in a decision to accept.
16. A method as claimed in Claim 15 substantially as herein described.
17. A method as claimed in Claim 15 substantially as illustrated in Figure 3 or 4 of the accompanying drawings.
PCT/GB1987/000702 1986-10-07 1987-10-05 Apparatus and method for controlling transmission of defects WO1988002700A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
NO882489A NO882489L (en) 1986-10-07 1988-06-06 DEVICE AND PROCEDURE FOR AA CHECK THE TRANSFER OF DEFECTS.
DK306588A DK306588D0 (en) 1986-10-07 1988-06-06 APPARATUS AND PROCEDURE FOR CHECKING THE DEFECT TRANSFER

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB868624013A GB8624013D0 (en) 1986-10-07 1986-10-07 Prevention of communicable disease
GB8624013 1986-10-07
GB868628345A GB8628345D0 (en) 1986-10-07 1986-11-27 Preventing transmission of defects
GB8628345 1986-11-27

Publications (1)

Publication Number Publication Date
WO1988002700A1 true WO1988002700A1 (en) 1988-04-21

Family

ID=26291390

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1987/000702 WO1988002700A1 (en) 1986-10-07 1987-10-05 Apparatus and method for controlling transmission of defects

Country Status (6)

Country Link
US (1) US5108131A (en)
EP (1) EP0487517A1 (en)
AU (1) AU8023787A (en)
DK (1) DK306588D0 (en)
GB (1) GB2199679A (en)
WO (1) WO1988002700A1 (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5308834A (en) * 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
US5770694A (en) * 1990-08-13 1998-06-23 Incyte Pharmaceuticals, Inc. Genetically engineered BPI variant proteins
US5873358A (en) * 1993-01-29 1999-02-23 Aradigm Corporation Method of maintaining a diabetic patient's blood glucose level in a desired range
US5888477A (en) * 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
US5915378A (en) * 1993-01-29 1999-06-29 Aradigm Corporation Creating an aerosolized formulation of insulin
US5970973A (en) * 1993-01-29 1999-10-26 Aradigm Corporation Method of delivering insulin lispro
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US6085753A (en) * 1993-01-29 2000-07-11 Aradigm Corporation Insulin delivery enhanced by coached breathing
US6131567A (en) * 1993-01-29 2000-10-17 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US6944767B1 (en) 2000-07-07 2005-09-13 Genaissance Pharmaceuticals, Inc. Methods and apparatus for ensuring the privacy and security of personal medical information
US8234128B2 (en) 2002-04-30 2012-07-31 Baxter International, Inc. System and method for verifying medical device operational parameters
US8775196B2 (en) 2002-01-29 2014-07-08 Baxter International Inc. System and method for notification and escalation of medical data
US10061899B2 (en) 2008-07-09 2018-08-28 Baxter International Inc. Home therapy machine
US10173008B2 (en) 2002-01-29 2019-01-08 Baxter International Inc. System and method for communicating with a dialysis machine through a network

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2305525B (en) * 1995-09-21 1997-08-20 Ricoh Kk Document data administrating system and method of administrating document data
US6042005A (en) * 1997-06-20 2000-03-28 Basile; Mark R. Personal identification and promotional system using personal and medical information
US6497358B1 (en) * 1999-09-13 2002-12-24 Christopher S. Walsh Record and verification method and system for radiation therapy
WO2003065300A1 (en) * 2002-01-28 2003-08-07 Lutz Guenter Universal personal identity card
US8554579B2 (en) 2008-10-13 2013-10-08 Fht, Inc. Management, reporting and benchmarking of medication preparation
EP3346444B1 (en) 2012-10-26 2020-09-23 Baxter Corporation Englewood Improved image acquisition for medical dose preparation system
EP3453377A1 (en) 2012-10-26 2019-03-13 Baxter Corporation Englewood Improved work station for medical dose preparation system
US11107574B2 (en) 2014-09-30 2021-08-31 Baxter Corporation Englewood Management of medication preparation with formulary management
SG11201704359VA (en) 2014-12-05 2017-06-29 Baxter Corp Englewood Dose preparation data analytics
JP2018507487A (en) 2015-03-03 2018-03-15 バクスター・コーポレーション・イングルウッドＢａｘｔｅｒ Ｃｏｒｐｏｒａｔｉｏｎ Ｅｎｇｌｅｗｏｏｄ Pharmacy workflow management with alert integration
DE102020113311A1 (en) 2020-05-15 2021-11-18 Bundesdruckerei Gmbh Method for generating a security document and using the security document and security system

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3502437A (en) * 1967-03-13 1970-03-24 Haematronics Inc Identification card
FR2167252A5 (en) * 1972-01-11 1973-08-24 Labo Physique Medicale
FR2229099A1 (en) * 1973-05-08 1974-12-06 Asea Ab
US3921318A (en) * 1973-01-22 1975-11-25 Anthony Calavetta Body-carried medical history card
US4236332A (en) * 1978-12-29 1980-12-02 Melchior P. Beller Medical history card
US4259391A (en) * 1978-10-30 1981-03-31 Brecht Frederick R Indicia bearing plastic laminate and method of producing same
GB2092952A (en) * 1981-02-18 1982-08-25 Silver David Selwyn Identification method
US4459015A (en) * 1982-07-19 1984-07-10 Brecht Frederick R Indicia bearing laminated cards and apparatus and method for producing indicia bearing laminated cards
US4632428A (en) * 1986-12-29 1986-12-30 Brown Steven P Combination medical data, identification and health insurance card

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790510A (en) * 1971-11-04 1973-02-15 Rothfjell Rolf E METHOD FOR THE IDENTIFICATION OF PERSONS USING SELECTED CHARACTERISTIC CURVES OF THE BODY
US4122947A (en) * 1978-01-27 1978-10-31 Falla Marjorie B Pre-packaged patient identification kit
US4318554A (en) * 1979-09-10 1982-03-09 Microseal Corporation Combined medical and/or informational identification credit card
GB2073660A (en) * 1980-04-10 1981-10-21 Miles K A Identity document
US4575127A (en) * 1985-01-18 1986-03-11 Data Medi-Card, Inc. Medical data card having internal illumination

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3502437A (en) * 1967-03-13 1970-03-24 Haematronics Inc Identification card
FR2167252A5 (en) * 1972-01-11 1973-08-24 Labo Physique Medicale
US3921318A (en) * 1973-01-22 1975-11-25 Anthony Calavetta Body-carried medical history card
FR2229099A1 (en) * 1973-05-08 1974-12-06 Asea Ab
US4259391A (en) * 1978-10-30 1981-03-31 Brecht Frederick R Indicia bearing plastic laminate and method of producing same
US4236332A (en) * 1978-12-29 1980-12-02 Melchior P. Beller Medical history card
GB2092952A (en) * 1981-02-18 1982-08-25 Silver David Selwyn Identification method
US4459015A (en) * 1982-07-19 1984-07-10 Brecht Frederick R Indicia bearing laminated cards and apparatus and method for producing indicia bearing laminated cards
US4632428A (en) * 1986-12-29 1986-12-30 Brown Steven P Combination medical data, identification and health insurance card

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5308834A (en) * 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
US5770694A (en) * 1990-08-13 1998-06-23 Incyte Pharmaceuticals, Inc. Genetically engineered BPI variant proteins
US6408854B1 (en) 1993-01-29 2002-06-25 Aradigm Corporation Insulin delivery enhanced by coached breathing
US6647987B2 (en) 1993-01-29 2003-11-18 Aradigm Corporation Insulin delivery enhanced by coached breathing
US5915378A (en) * 1993-01-29 1999-06-29 Aradigm Corporation Creating an aerosolized formulation of insulin
US5970973A (en) * 1993-01-29 1999-10-26 Aradigm Corporation Method of delivering insulin lispro
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US6085753A (en) * 1993-01-29 2000-07-11 Aradigm Corporation Insulin delivery enhanced by coached breathing
US6098615A (en) * 1993-01-29 2000-08-08 Aradigm Corporation Method of reproducibly effecting a patient's glucose level
US6131567A (en) * 1993-01-29 2000-10-17 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US6250298B1 (en) 1993-01-29 2001-06-26 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US5873358A (en) * 1993-01-29 1999-02-23 Aradigm Corporation Method of maintaining a diabetic patient's blood glucose level in a desired range
US6427681B1 (en) 1993-01-29 2002-08-06 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US6431166B2 (en) 1993-01-29 2002-08-13 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US6431167B1 (en) 1993-01-29 2002-08-13 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US5888477A (en) * 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
US7490603B2 (en) 1993-01-29 2009-02-17 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US7021309B2 (en) 1993-01-29 2006-04-04 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US6944767B1 (en) 2000-07-07 2005-09-13 Genaissance Pharmaceuticals, Inc. Methods and apparatus for ensuring the privacy and security of personal medical information
US8775196B2 (en) 2002-01-29 2014-07-08 Baxter International Inc. System and method for notification and escalation of medical data
US10173008B2 (en) 2002-01-29 2019-01-08 Baxter International Inc. System and method for communicating with a dialysis machine through a network
US10556062B2 (en) 2002-01-29 2020-02-11 Baxter International Inc. Electronic medication order transfer and processing methods and apparatus
US8234128B2 (en) 2002-04-30 2012-07-31 Baxter International, Inc. System and method for verifying medical device operational parameters
US10061899B2 (en) 2008-07-09 2018-08-28 Baxter International Inc. Home therapy machine
US10068061B2 (en) 2008-07-09 2018-09-04 Baxter International Inc. Home therapy entry, modification, and reporting system
US10095840B2 (en) 2008-07-09 2018-10-09 Baxter International Inc. System and method for performing renal therapy at a home or dwelling of a patient
US10224117B2 (en) 2008-07-09 2019-03-05 Baxter International Inc. Home therapy machine allowing patient device program selection
US10089443B2 (en) 2012-05-15 2018-10-02 Baxter International Inc. Home medical device systems and methods for therapy prescription and tracking, servicing and inventory

Also Published As

Publication number Publication date
EP0487517A1 (en) 1992-06-03
DK306588A (en) 1988-06-06
GB8723357D0 (en) 1987-11-11
AU8023787A (en) 1988-05-06
DK306588D0 (en) 1988-06-06
US5108131A (en) 1992-04-28
GB2199679A (en) 1988-07-13

Similar Documents

Publication Publication Date Title
US5108131A (en) Method of controlling transmission of defects
US5381487A (en) Patient identification system
CA2008243C (en) Patient identification system
WO2000013588A1 (en) Verification of human medical data
Meyer The wandering uterus: Politics and the reproductive rights of women
JPH10508970A (en) System for controlling the spread of HIV / AIDS and other infectious diseases
CA2254962A1 (en) Method and apparatus for ascertaining medical conditions
Wojcik Muted consent: a casebook in modern medical ethics
Kalender Subtle pressures, coercive sterilizations and denials of access: A trans-crip approach to reproductive subjectivation.
Hoffman You Say Adoption, I Say Objection: Why the Word War Over Embryo Disposition Is More Than Just Semantics
Richards Don't Take Your Organs to Heaven... Heaven Knows We Need Them Here: Another Look at the Required Response System
Haimes Family Connections: The management of biological origins in the new reproductive technologies
Miranda et al. Gathering donor history: Ensuring safe tissues for transplant
Randhawa The changing nature of organ procurement policies and the implications for the UK
Т. De George Biomedical ethics
Hogle Public good, private protections: Competing values in German transplantation law
Al Mansouri et al. A Survey on the Emerging Trend of Human Microchip Implants And Their Potential
Price Matchmaking in the clinic: gamete donation and the management of difference
Shaw et al. Semen collection in adolescents with cancer
Bat-Ireedui et al. The Study of Current Legislative Statement of Organ Transplantation
Toshima et al. Why is heart transplantation not performed in Japan? Refutation of Dr Yoshio Watanabe's arguments against heart transplantation
Cohen Increasing the Supply of Transplant Organs: The Virtues of a Futures Market
JP2003527715A (en) How to register, store and use human substances and / or information derived from them anonymously
Ostrowski et al. Infective endocarditis on natural and prosthetic valves
Fisher The Perspective of Medical Ethics

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU DK FI JP KR NO SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1987906441

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1987906441

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1987906441

Country of ref document: EP